Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B, Grimaldi F, Ammirati L, Annunziata M, De Santis G, Perrotta A, De Novellis D, Giudice V, Morini D, Storti G, Califano C, Risitano AM, Pane F, Selleri C.
Serio B, et al. Among authors: perrotta a.
Cancer Rep (Hoboken). 2024 Apr;7(4):e2044. doi: 10.1002/cnr2.2044.
Cancer Rep (Hoboken). 2024.
PMID: 38662362
Free PMC article.